Occupational Activity – Page 25

Merck KGaA Remains Optimistic About CDMO Business Prospects Amidst Q1 Downturn

11 months ago talkbio0Tagged business career, CDMO, Drug Industry, first-quarter, Merck KGaA, Optimism, slump

Merck KGaA, CDMO, first-quarter, slump, optimism, business prospects, pharmaceutical industry.

Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership

11 months ago talkbio0Tagged Biotechnology, Cancer Therapeutic Procedure, CAR-T, decentralized, expansion, Galapagos, healthcare innovation, Immunotherapy, Manufacture, nationwide, Partnership

Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

11 months ago talkbio0Tagged Administration occupational activities, Clinical Trials, Diabetes, Drug Industry, Eli Lilly, Insulin, insulin therapy, Nordisk, Primary Endpoint, trials, Weekly

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study

12 months ago talkbio0Tagged Administration occupational activities, Benefit, Cardiovascular system, Clinical Research, Diabetes, Glucagon-Like Peptide-1 Receptor, heart health, Obesity, Wegovy

Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.

Revolutionizing Healthcare: Streamlining Cell and Gene Therapy Manufacturing (Part 1)

12 months ago talkbio0Tagged Biotechnology, Cell Therapy, Cost Effectiveness, gene therapy, healthcare innovation, Manufacture, Precision Medicine, production, regulatory, scalability

Cell therapy, gene therapy, manufacturing, biotechnology, healthcare innovation, personalized medicine, production challenges, regulatory compliance, scalability, cost-effectiveness.

Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing

12 months ago talkbio0Tagged Automation, biomanufacturing, CAR-T, Cell Therapy, gene therapy, Manufacture, Precision Medicine, regulatory, scale-up, Stem Cell Therapy, Viral Vector

Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

12 months ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Attovia Secures $105M for Multiple Trials of Innovative Industrial and Institutional Biologics

12 months ago talkbio0Tagged Attovia, Biological Factors, Clinical Trials, crossover investors, Industry, institutional

Attovia, biologics, industrial and institutional (I&I), crossover investors, funding, clinical trials

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief

12 months ago talkbio0Tagged Andrew Baum, Chief, Citi, Drug Industry, Leadership Change, Pfizer, Strategic Planning, Strategy

Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.